A Phase I/II Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
Status:
Recruiting
Trial end date:
2027-05-20
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label, multicenter, dose-escalation, and dose-expansion phase I/II
clinical study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and
efficacy of LBL-034 in patients with R/R MM.